Gillette R W, Berringer D C, Wunderlich D A
J Natl Cancer Inst. 1978 Jun;60(6):1427-32. doi: 10.1093/jnci/60.6.1427.
Immunization with trinitrophenyl (TNP)-derivatized allogeneic lymphoma cells resulted in significant immunity to poorly immunogenic syngeneic lymphoma cells. Neither TNP-treated nor X-irradiated syngeneic lymphoma cells were immunogenic under similar experimental conditions. Immunization with untreated allogeneic lymphoma cells produced only minimal levels of resistance to challenge with syngeneic lymphoma cells. The complete set of antigens responsible for the immunity was carried exclusively on transformed lymphocytes because allogeneic TNP-derivatized lymph node and thymus cells also did not immunize. The immunity was transferred to nonimmune inbred BALB/c and A/J mice by spleen cells from immune donors. The Winn assay was used to measure the antilymphoma immunity in vivo. When immune spleen cell-lymphoma mixtures were inoculated sc at a ratio of 1,000:1, nonimmune mice were completely protected. Reactivity of immune lymphocytes to syngeneic lymphoma cells was also demonstrated in vitro by the 51Cr-release method. Immunization with TNP-derivatized allogeneic lymphoma cells resulted in measurable immune resistance to inocula of viable syngeneic tumor cells in excess of 100 times the tumorigenic dose. Induction of immunity to syngeneic lymphoma cells strictly required that the immunizing cells be histoincompatible at the major H-2 locus and possess tumor-specific antigen(s). Maximum immune sensitivity was observed only after chemical modification of the immunizing allogeneic lymphoma cells.
用三硝基苯基(TNP)衍生的同种异体淋巴瘤细胞进行免疫可产生对免疫原性差的同基因淋巴瘤细胞的显著免疫力。在类似实验条件下,经TNP处理或X射线照射的同基因淋巴瘤细胞均无免疫原性。用未处理的同种异体淋巴瘤细胞进行免疫,对同基因淋巴瘤细胞攻击产生的抵抗力仅处于最低水平。负责这种免疫的全套抗原仅存在于转化的淋巴细胞上,因为同种异体TNP衍生的淋巴结和胸腺细胞也不能起到免疫作用。这种免疫力可通过免疫供体的脾细胞转移至无免疫力的近交系BALB/c和A/J小鼠。采用Winn试验在体内测量抗淋巴瘤免疫力。当以1000:1的比例将免疫脾细胞 - 淋巴瘤混合物皮下接种时,无免疫力的小鼠得到完全保护。通过51Cr释放法在体外也证明了免疫淋巴细胞对同基因淋巴瘤细胞的反应性。用TNP衍生的同种异体淋巴瘤细胞进行免疫可产生对超过致瘤剂量100倍的活同基因肿瘤细胞接种物的可测量免疫抵抗力。诱导对同基因淋巴瘤细胞的免疫力严格要求免疫细胞在主要H-2位点上组织不相容并拥有肿瘤特异性抗原。仅在对免疫同种异体淋巴瘤细胞进行化学修饰后才观察到最大免疫敏感性。